Sun Pharma arm launches breast cancer drug Palbociclib in India
Advertisement
Mumbai: Sun Pharmaceutical Industries Limited toay announced that one of its wholly-owned subsidiaries has launched a novel anti-cancer drug, Palbociclib in India for patients who have advanced breast cancer, the most common cancer among women in the country.
The company will make the drug available under the brand name, PALENO (Palbociclib) 75 mg, 100 mg, 125 mg
Kirti Ganorkar, CEO – India Business, Sun Pharma, said "We are introducing Palbociclib at an affordable price which will help improve patient access. PALENO will address the treatment need of several advanced breast cancer patients in India. For the first time, we are introducing a unique patient assistance program that will improve patient compliance and accessibility."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.